Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists

Hojabr Kakavand; James S. Wilmott; Georgina V. Long; Richard A Scolyer

doi:10.1016/j.pathol.2015.12.010

Back

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists

Article 2016 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Julia Lai‐Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford

Article2018

The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors

Julia Lai‐Kwon, Christine Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long